Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999699 · ClinicalTrials.gov registry record · Phase 1
A Study of the Immune Response to Heplisav in Healthy Older Adults
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01999699: Completed Phase 1 study, sponsored by Dynavax Technologies Corporation.
NCT01999699 is a Phase 1 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01999699, a Phase 1 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.
Interventions
- BIOLOGICAL HEPLISAV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT01999699 record still lists
NCT01999699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which HEPLISAV is the first listed.
NCT01999699 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01999699 about?
NCT01999699 is a clinical study titled "A Study of the Immune Response to Heplisav in Healthy Older Adults". This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.
What is the current status of trial NCT01999699?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2013-11. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01999699?
The interventions under investigation include: HEPLISAV (BIOLOGICAL).
Who is sponsoring clinical trial NCT01999699?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01999699's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia